An injectable long-acting release version, exenatide LAR, with a more convenient once-weekly dosing is currently being tested in a head-to-head Phase III trial against exenatide, with results ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

Experts had hoped a medication called exenatide, a weight loss jab in the same class of drugs as Ozempic and Wegovy, could help combat the degenerative nerve condition. But University College of ...